In vivo bioequivalence study of Imatinib 100 mg capsule
Not Applicable
Recruiting
- Conditions
- Fasted state in vivo bioequivalence study.
- Registration Number
- IRCT20210519051345N6
- Lead Sponsor
- Tabriz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health including Liver, Heart and Kidney health
Being at the age of 25-55 years old
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Pregnancy
Alcohol and drug addiction
History of drug allergy
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug Plasma Concentration. Timepoint: Blood samples will be obtained prior to dosing (baseline) and 0.5; 1.0; 1.5; 2.0; 2.5; 3.0; 3.5, 4.0; 4.5, 6.0; 8.0; 12.0; 24.0; 48.0 and 72.0 h post-dose. Method of measurement: High performance liquid chromatography (HPLC).
- Secondary Outcome Measures
Name Time Method